Ziconotide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ziconotide: From Unspecified Original Indication to Migraine Disorder
One-Sentence Summary
Ziconotide’s original indication and mechanism of action are not documented in the current evidence pack (data gap), and the drug is not marketed in Taiwan. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 1 publication (a single case report) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (data gap) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for the drug record itself is not available (original_moa is flagged as a data gap). However, the evidence pack’s repurposing rationale for this candidate provides mechanistic detail: Ziconotide is a selective N-type (Cav2.2) voltage-gated calcium channel blocker acting at primary afferent nerve terminals in the spinal dorsal horn, where it inhibits release of pain-related neurotransmitters including substance P, glutamate, and CGRP.
This mechanism has a theoretical overlap with migraine pathophysiology, which involves trigeminovascular system sensitization and CGRP release. That said, this connection is currently supported only by a single intrathecal case report, without any systematic clinical trials. Ziconotide’s intrathecal administration also carries well-known serious neuropsychiatric adverse effects (cognitive impairment, hallucinations), so any exploration of this indication would require careful risk-benefit assessment.
Because original indication data is not available in this evidence pack, a direct comparison between the original and predicted indications cannot be made at this time; this assessment relies solely on the mechanistic rationale documented above.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26392785 | 2015 | Case Report | Journal of Pain Research | Resolution of chronic migraine headaches following intrathecal ziconotide administration; ziconotide described as an N-type calcium channel blocker used for chronic severe pain without tolerance/dependency issues seen with opioids |
Taiwan Market Information
No marketing authorizations are currently on record for ziconotide in Taiwan (total_licenses: 0, market_status: 未上市).
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and drug-drug interaction data are all flagged as blocking data gaps in this evidence pack — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting the migraine indication is currently limited to a single case report (L4, no clinical trials), the drug is not marketed in Taiwan, and safety data (warnings, contraindications, drug interactions) are entirely unavailable — including a Blocking-severity gap (TFDA label warnings/contraindications) that prevents this candidate from advancing past the initial safety screening stage.
To proceed, the following is needed:
- TFDA label warnings and contraindications (Blocking gap — required before any S1 safety assessment)
- Confirmed mechanism of action data via DrugBank (High-priority gap)
- Systematic clinical evidence (case series, observational study, or trial) beyond the single existing case report
- Explicit evaluation of intrathecal-route feasibility and risk-benefit profile given known neuropsychiatric adverse effects, before considering migraine as a research direction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.